All In Biotech

NDA 204370 · Abbvie

Vraylar

Cariprazine Hydrochloride · Oral · Atypical Antipsychotic

Novel

Last checked: Nov 20, 2026Latest source record: Dec 18, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2015

Sep 17, 2015

Approved uses

9

Original approval plus efficacy supplements

Registered trials

53

23 Phase 3, 6 recruiting

FAERS reports

9,636

3,459 serious, 258 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS and SUICIDAL THOUGHTS AND BEHAVIORS Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. VRAYLAR is not approved for the treatment of patients with dementia-related psychosis [see Warnings and Precautions ( 5.1 )]. Suicidal Thoughts and Behaviors Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for the emergence of suicidal thoughts and behaviors [see Warnings and Precautions ( 5.2 )] . The safety and effectiveness of VRAYLAR have not been established in pediatric patients [see Use in Specific Populations ( 8.4 )]....

What it is approved for

From the label in effect Nov 11, 2026.

VRAYLAR ® is indicated for: Treatment of schizophrenia in adults [see Clinical Studies ( 14.1 )] Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults [see Clinical Studies ( 14.2 )] Treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in adults [see Clinical Studies ( 14.3 )] Adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults [see Clinical Studies ( 14.4 )] VRAYLAR is an atypical antipsychotic indicated for: Treatment of schizophrenia in adults ( 1 ) Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults ( 1 ) Treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in adults ( 1 ) Adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults ( 1 )

Mechanism: The mechanism of action of cariprazine is unknown. However, the efficacy of cariprazine could be mediated through a combination of partial agonist activity at central dopamine D 2 and serotonin 5-HT 1A receptors and antagonist activity at serotonin 5-HT 2A receptors. Cariprazine forms two major metabolites, desmethylcariprazine (DCAR) and didesmethylcariprazine (DDCAR), that have in vitro receptor binding profiles similar to the parent drug.

Therapeutic areas: Psychiatry

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 18, 2025 Supplement 17 · Efficacy · priority review LetterLabel
  • Dec 18, 2025 Supplement 15 · Efficacy · priority review LetterLabel
  • Dec 18, 2025 Supplement 16 · Efficacy · priority review LetterLabel
  • Dec 18, 2025 Supplement 14 · Efficacy LetterLabel
  • Dec 16, 2022 Supplement 9 · Efficacy LabelLetterReview
  • May 24, 2019 Supplement 6 · Efficacy LabelLetterReview
  • Nov 9, 2017 Supplement 2 · Efficacy LabelLetter
  • Sep 17, 2015 Original approval · Type 1 - New Molecular Entity NovelLabelLetterReview
  • Sep 17, 2015 Original approval · Efficacy Novel
6 products under this application
  • VRAYLAR · CARIPRAZINE HYDROCHLORIDE EQ 0.75MG BASE · CAPSULE, ORAL · Prescription
  • VRAYLAR · CARIPRAZINE HYDROCHLORIDE EQ 6MG BASE · CAPSULE, ORAL · Prescription · TE AB
  • VRAYLAR · CARIPRAZINE HYDROCHLORIDE EQ 3MG BASE · CAPSULE, ORAL · Prescription · TE AB
  • VRAYLAR · CARIPRAZINE HYDROCHLORIDE EQ 0.5MG BASE · CAPSULE, ORAL · Prescription
  • VRAYLAR · CARIPRAZINE HYDROCHLORIDE EQ 4.5MG BASE · CAPSULE, ORAL · Prescription · TE AB
  • VRAYLAR · CARIPRAZINE HYDROCHLORIDE EQ 1.5MG BASE · CAPSULE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Cariprazine" as an intervention, any sponsor and status, largest first.

All 53 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use1,083
  • drug ineffective566
  • weight increased501
  • akathisia434
  • anxiety392
  • tardive dyskinesia392
  • tremor378
  • nausea373
  • fatigue368
  • insomnia354
  • suicidal ideation337
  • depression296

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20112
20151
2016156
2017337
2018415
2019890
20201,030
2021853
2022850
20231,259
20241,294
20251,516
20261,033

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Vraylar (Cariprazine HCl)

2024 spending

$1.14B

Beneficiaries

117,573

766,962 claims

Per beneficiary

$9,662

$48.73 per unit

View as table
YearSpending
2020$487,495,093
2021$583,108,993
2022$708,765,555
2023$935,653,082
2024$1,135,973,310

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 131 on PubMed

Sponsor: AbbVie

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.